

## MARKET RELEASE

### MedAdvisor requests extended voluntary trading suspension

Melbourne, Australia, 10 November, 2020 - MedAdvisor Limited (**MedAdvisor**) (ACN 145 327 617, ASX: MDR) has today requested an extension to its voluntary suspension as the company continues to work towards the acquisition of US-based Adheris Health.

The reason for the further voluntary suspension is a result of institutional investors, participating in the Offer, requesting further briefings with the Company and Adheris. Due to time zone differences with the US, the Company requires further time to schedule these briefings.

The Initial voluntary suspension was expected to end on the opening of trading on Tuesday, 10 November 2020.

The Company requests that a further voluntary suspension of the Company's securities from the commencement of trading on Tuesday, 10 November 2020 until the earliest of:

- (a) such time as the Company makes an announcement to the market in relation to the outcome of the institutional component of the Offer;
- (b) the open of trading on Thursday, 12 November 2020; and
- (c) the Company separately requests that the voluntary suspension be lifted.

MedAdvisor expects that the ASX announcement about the outcome of the institutional component of the Offer as soon as possible, and in any event, prior to the open of trading on Thursday, 12 November 2020.

#### Offer timetable

An indicative timetable of the key dates in respect of the Entitlement Offer is set out below:

Request 'back-to-back' trading halt and anticipated two days voluntary suspension before market open	Monday, 2 November 2020
Announcement of Acquisition, Entitlement Offer and Placement; Release of Investor Presentation, Appendix 3B and 708AA Cleansing Notice (Entitlement Offer)	Before 12 noon AEDT on Monday, 2 November 2020
Announcement of change to Entitlement Offer price; Release of revised investor Presentation, Appendix 3B and 708AA Cleansing Notice (Entitlement Offer)	Before 12 noon AEDT on Friday, 6 November 2020

Request for two further days of voluntary suspension	Before market open, Tuesday, 10 November 2020
Conduct Institutional offer before the resumption of trading following the trading halt and suspension	Friday, 6 November 2020 to Wednesday, 11 November 2020
Announcement of Placement and Institutional Entitlement Offer results; come out of voluntary suspension	Before market open, Thursday, 12 November 2020
Record Date for eligibility in the Entitlement Offer	7.00pm on Thursday, 12 November 2020
Settlement of the New Shares issued under the Institutional Entitlement Offer and Placement	Monday, 16 November 2020
Allotment and normal trading on ASX of New Shares issued under the Institutional Entitlement Offer; 708A Cleansing Notice (Placement)	Tuesday, 17 November 2020
Completion of Adheris acquisition	Tuesday, 17 November 2020
Retail Entitlement Offer opens and Retail Offer Booklet despatched	Tuesday, 17 November 2020
Retail Entitlement Offer closes	5.00pm on Tuesday, 1 December 2020
Announce results of Retail Entitlement Offer; Settlement of the New Shares issued under the Retail Entitlement Offer	Friday, 4 December 2020
Allotment of New Shares issued under the Retail Entitlement Offer; Appendix 2A	Tuesday, 8 December 2020
Normal trading on ASX of New Shares issued under the Retail Entitlement Offer	Wednesday, 9 December 2020
Annual General Meeting	Monday, 21 December 2020

### **Further information**

Further details of the Acquisition and the Offer are set out in the investor presentation provided to the ASX last week. The Investor Presentation contains important information including key risks and foreign selling restrictions with respect to the Entitlement Offer.

If you have any questions, you should seek advice from your stockbroker, accountant or other independent and appropriately licensed professional advisor.

For further information about the Entitlement Offer, you can call the MedAdvisor shareholder information line on +61 2 8651 7816 at any time between 9.00am and 4.30pm (AEST) on Monday to Friday.

- ENDS -

**For more information:**

Simon Glover  
Chief Financial Officer  
corporate@medadvisor.com.au  
+61 3 9095 3036

Alex Beashel  
Corporate Communications  
ab@alexbeashel.com  
+61 466 308 667

**About MedAdvisor**

*MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.7 million users through more than 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100.*

Carlo Campiciano - Company Secretary  
MedAdvisor Limited  
(ACN 145 327 617)  
Level 2  
971 Burke Road  
Camberwell Vic 3124